

58. The T cell activating bispecific antigen binding molecule of any one of claims 1 to 51 or 56 or the pharmaceutical composition of claim 57 for use as a medicament.

59. The T cell activating bispecific antigen binding molecule of any one of claims 1 to 51 or 56 or the pharmaceutical composition of claim 57 for use in the treatment of a disease in an individual in need thereof.

60. The T cell activating bispecific antigen binding molecule or the pharmaceutical composition of claim 59, wherein the disease is cancer.

61. Use of the T cell activating bispecific antigen binding molecule of any one of claims 1 to 51 or 56 for the manufacture of a medicament for the treatment of a disease in an individual in need thereof.

62. A method of treating a disease in an individual, comprising administering to said individual a therapeutically effective amount of a composition comprising the T cell activating bispecific antigen binding molecule of any one of claims 1 to 51 or 56 in a pharmaceutically acceptable form.

63. The use of claim 61 or the method of claim 62, wherein said disease is cancer.

64. A method for inducing lysis of a target cell, comprising contacting a target cell with the T cell activating bispecific antigen binding molecule of any one of claims 1-51 or 56 in the presence of a T cell.

~~65. The invention as described hereinbefore.~~